HR 349
117th Congress
House
Health
Cardiovascular and respiratory health
Congressional oversight
Emergency medical services and trauma care
Health promotion and preventive care
Health technology, devices, supplies
Immunology and vaccination
Infectious and parasitic diseases
Manufacturing
Public contracts and procurement
Research and development
Coronavirus Vaccine and Therapeutic Development Act of 2021
Introduced: January 19, 2021
See on congress.gov
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 5, 2021
Sponsor introductory remarks on measure. (CR H393)
Feb 2, 2021
Referred to the Subcommittee on Health.
Jan 19, 2021
Referred to the House Committee on Energy and Commerce.
Jan 19, 2021
Introduced in House
Plain-English summary
Coronavirus Vaccine and Therapeutic Development Act of 2021
This bill directs the Department of Health and Human Services (HHS) to increase the supply of vaccines and medical products that prevent or control COVID-19 (i.e., coronavirus disease 2019). To increase supplies, HHS must, as appropriate, award grants and enter other transactions to expand relevant research, procurement, and production activities.
HHS must report to Congress on these actions. The report must assess and detail plans to enhance the supply chain and manufacturing capacity for the vaccines and products. It must also include plans to support domestic and international vaccination programs.
What's happening now
Sponsor introductory remarks on measure. (CR H393)
Committees of jurisdiction
2